# 21 CFR 314.101 Filing an NDA and receiving an ANDA.

21 CFR 314.101 Filing an NDA and receiving an ANDA., “Filing an NDA and receiving an ANDA”, is a CFR section of [21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications](https://ontology.bommaritollc.com/id/01a0f094-b5f3-717b-b604-e7b462cd0e7c); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter D—DRUGS FOR HUMAN USE](https://ontology.bommaritollc.com/id/01a0f094-b5e4-722f-99b0-5c1856aef2a9) › [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858) › [21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications](https://ontology.bommaritollc.com/id/01a0f094-b5f3-717b-b604-e7b462cd0e7c)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 314.101](https://ontology.bommaritollc.com/id/01a0f094-c4ce-7070-a0fa-40d31609fcff)
- `eli:cites`:
  - [Subchapter I—Administration and Miscellaneous Provisions](https://ontology.bommaritollc.com/id/01a0f07c-d2a8-71a0-898c-d3e3cf9ebb25)
  - [21 CFR Part 50—Protection of human subjects](https://ontology.bommaritollc.com/id/01a0f094-b7f0-7092-8cfc-6d60da0417f5)
  - [21 CFR Part 56—Institutional Review Boards](https://ontology.bommaritollc.com/id/01a0f094-b7f2-72a4-82d6-ac180848fce4)
  - [21 CFR Part 58—Good laboratory practice for nonclinical laboratory studies](https://ontology.bommaritollc.com/id/01a0f094-b7f3-722a-bdd9-43216f95ec63)
  - [21 CFR 25.30 General.](https://ontology.bommaritollc.com/id/01a0f094-bb91-7368-898e-36fe349f7c44)
  - [21 CFR 25.31 Human drugs and biologics.](https://ontology.bommaritollc.com/id/01a0f094-bb92-7065-981f-4d5ba7337f0c)
  - [21 CFR 25.40 Environmental assessments.](https://ontology.bommaritollc.com/id/01a0f094-bb96-753f-a17a-23785c940d8f)
  - [21 CFR 314.50 Content and format of an NDA.](https://ontology.bommaritollc.com/id/01a0f094-c4bc-7545-b254-0ac4503aaeb2)
  - [21 CFR 314.94 Content and format of an ANDA.](https://ontology.bommaritollc.com/id/01a0f094-c4c8-71bf-84d4-b49661b2234c)
  - [21 CFR 314.99 Other responsibilities of an applicant of an ANDA.](https://ontology.bommaritollc.com/id/01a0f094-c4cc-77aa-bc94-950bc3a39a8c)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a4c48e4fe8)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e31f-7681-a8c3-c3c17b6c0fe7)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d0-c51a-729f-b90c-51e723ecf6c4)
  - [evidence from https://www.govinfo.gov/link/cfr/21/314?sectionnum=101&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-67c6-724d-8eb8-cb4e99e7b7ba)
- `schema:isPartOf`: [21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications](https://ontology.bommaritollc.com/id/01a0f094-b5f3-717b-b604-e7b462cd0e7c)
- `schema:legislationIdentifier`: 21 CFR 314.101
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: Filing an NDA and receiving an ANDA
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/314?sectionnum=101&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/314?sectionnum=101&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 314.101 Filing an NDA and receiving an ANDA.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/314?sectionnum=101&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (5; `eli:cites`):
  - [21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb)
  - [21 CFR 314.125 Refusal to approve an NDA.](https://ontology.bommaritollc.com/id/01a0f094-c4d5-7607-9f58-27d7aa7b26b8)
  - [21 CFR 314.3 Definitions.](https://ontology.bommaritollc.com/id/01a0f094-c4bb-7201-9480-587d70211b58)
  - [21 CFR 314.52 Notice of certification of invalidity, unenforceability, or noninfringement of a patent.](https://ontology.bommaritollc.com/id/01a0f094-c4bd-769d-9072-4758085a0a1a)
  - [21 CFR 314.60 Amendments to an unapproved NDA, supplement, or resubmission.](https://ontology.bommaritollc.com/id/01a0f094-c4c0-7769-af86-f1aebc4ef691)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4)
Cite as: 21 CFR 314.101 Filing an NDA and receiving an ANDA.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
